After over two decades of providing trusted solutions for ocular surface disease, BioTissue is charting new territory with the introduction of CAM360 AmnioGraft (CAM360 AG)—a ringless, shelf-stable cryopreserved amniotic membrane. Building on the success of its well-known Prokera corneal bandage, CAM360 AG offers eye care professionals (ECPs) a flexible, innovative option for treating mild to moderate dry eye and early-stage neurotrophic keratitis (NK).
“We’ve spent more than 20 years earning the trust of physicians with Prokera,” says Tiffany Matthews, vice president of marketing at BioTissue. “Now, CAM360 AG builds on that legacy while introducing an option that empowers physicians with more versatility.”
VERSATILITY AND CONVENIENCE
CAM360 AG can be used under a bandage contact lens or paired with a collagen shield, offering physicians flexibility in managing a range of ocular surface conditions. The product’s shelf-stable nature is a game changer, simplifying inventory management and ensuring readiness when needed.
“Physicians are telling us how much they appreciate the versatility and convenience,” says Matthews. “Whether they’re treating dry eye patients or preparing the ocular surface before cataract surgery, CAM360 AG feedback suggests that it can deliver noticeable results in 48 hours.”
The early feedback from BioTissue’s progressive launch, which includes distributing 6,000 units to a subset of ECPs, has been overwhelmingly positive. Matthews highlights that both patients and physicians have reported broad satisfaction with CAM360 AG’s impact.
EXPANDING TREATMENT OPTIONS
BioTissue envisions CAM360 AG becoming an integral part of care for patients with more mild ocular conditions. “This product enables ECPs to start conversations about treatment earlier in the disease process,” says Matthews. “By providing them a versatile tool, we’re addressing the multifactorial challenges of dry eye disease while giving patients an option specifically developed to optimize comfort.”
For ECPs, CAM360 AG offers an opportunity to see patients back within three days for reassessment, an aspect that Matthews believes enhances patient engagement and outcomes. While CAM360 AG is poised to become more widely available in 2025, Prokera remains a valuable option.
COMMITMENT TO INNOVATION
As BioTissue executes this launch, the company is focused on supporting ECPs through the complexities of patient care, including reimbursement and evolving treatment protocols. “We understand the challenges ECPs face with patient expectations and practice logistics,” Matthews says. “Our goal is to provide solutions that address these complexities while staying passionate about advancing ocular surface care.”
“Innovation and evolution are essential,” she says. “This is just the beginning.”
Read more news from Women In Optometry here.
